Search results for " risperidone"

showing 4 items of 4 documents

Idiopathic granulomatous mastitis associated with risperidone: case report

2013

Granulomatous mastitis risperidone breast neoplasms

A systematic review and combined analysis of therapeutic drug monitoring studies for longacting risperidone

2017

Introduction: This systematic review of therapeutic drug monitoring (TDM) identifies three long-acting injectable (LAI) risperidone formulations. Areas covered: Limited data is available on two formulations (RBP-7000 and in Situ Microparticle), but 20 TDM articles on the microsphere formulation were found. Risperidone TDM includes the serum concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, used for calculating: 1) the risperidone/9-hydroxyrisperidone (R/9-OH-R) ratio (a measure of CYP2D6; values >1 are indicative of a CYP2D6 poor metabolizer) and 2) the total risperidone concentration-to-dose (C/D) ratio (a measure of risperidone clearance with a normal value…

CYP2D6Therapeutic drug monitoring studiesAdministration OralPharmacologyMicrosphereInjections03 medical and health sciences0302 clinical medicineLong acting risperidonePaliperidone PalmitatemedicineAnimalsHumansPharmacology (medical)General Pharmacology Toxicology and Pharmaceutics610 Medicine & healthActive metabolitePaliperidone PalmitateRisperidonemedicine.diagnostic_testbusiness.industryGeneral MedicineRisperidoneMicrospheres030227 psychiatryAntipsychotic agents/administration & dosage; delayed-action preparations; drug monitoring; injections; risperidone/administration & dosage; risperidone/blood; risperidone/metabolism; risperidone/pharmacokinetics; risperidone/pharmacology; risperidone/therapeutic use; schizophrenia/drug therapyTherapeutic drug monitoringDelayed-Action PreparationsDrug Monitoringbusiness030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents

researchProduct

Similar subjective response and adherence rates for long-acting risperidone and conventional depots

2008

Background and Aims:Amongst oral antipsychotics, tolerance and adherence are thought to be higher with atypicals versus conventional agents. Fewer data exist for parenteral antipsychotics regarding the atypical–conventional comparison.Aim:to compare adherence rates and subjective response between long-acting risperidone (LAR) and conventional depots.Methods:Cross-sectional, naturalistic, one-site study of all outpatients with severe mental disorders treated with injectable antipsychotics over a 12–month period at one Spanish mental health unit. Different sets of broadly– and narrowly–defined criteria for adherence were calculated from mental health nurse´s registry data. Patients´ subjectiv…

Psychiatry and Mental healthmedicine.medical_specialtySubjective responseRisperidoneSevere Mental Disordersbusiness.industryInternal medicineLong acting risperidonemedicineRegistry databusinessMental healthmedicine.drugEuropean Psychiatry

researchProduct

Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic…

2021

Background Recent guidelines suggested a wider use of long-acting injectable antipsychotics (LAI) than previously, but naturalistic data on the consequences of LAI use in terms of discontinuation rates and associated factors are still sparse, making it hard for clinicians to be informed on plausible treatment courses. Objective Our objective was to assess, under real-world clinical circumstances, LAI discontinuation rates over a period of 12 months after a first prescription, reasons for discontinuation, and associated factors. Methods The STAR Network ‘Depot Study’ was a naturalistic, multicentre, observational prospective study that enrolled subjects initiating a LAI without restrictions …

MalePediatricsrespectively)0302 clinical medicineDelayed-Action PreparationBrief Psychiatric Rating ScalePharmacology (medical)he STAR Network ‘Depot Study’ prospectively followed 394 subjects initiating treatment with long-acting injections (LAIs) of antipsychotics under naturalistic conditions for 12 months. LAI discontinuation was frequent in everyday clinical practice in ItalyOriginal Research ArticleProspective StudiesProspective cohort studytreatmentMental DisordersHazard ratiowhereas more than half of participants initiating risperidone LAI and olanzapine LAI discontinued during the 12 months of follow-up (51.4 and 62.5%Psychiatric Status Rating ScaleMiddle Agedside efectsPsychiatry and Mental healthItalyMental DisorderFemalehe STAR Network ‘Depot Study’ prospectively followed 394 subjects initiating treatment with long-acting injections (LAIs) of antipsychotics under naturalistic conditions for 12 months. LAI discontinuation was frequent in everyday clinical practice in Italy occurring in almost 40% of the entire sample; side efects participant refusal to continue LAIs and LAIs no longer being required were the most frequently reported reasons for discontinuation. Paliperidone LAI and aripiprazole LAI were the least discontinued medications (33.9 and 35.4% respectively) whereas more than half of participants initiating risperidone LAI and olanzapine LAI discontinued during the 12 months of follow-up (51.4 and 62.5% respectively). In multivariate analysis being prescribed olanzapine LAI and poor medication adherence at baseline were signifcantly associated with higher discontinuation risk.HumanAntipsychotic Agentsmedicine.drugPsychopathologyAdultmedicine.medical_specialtyDiscontinuationFollow-Up StudieMedication Adherence03 medical and health sciencesmedicineHumansPaliperidoneAdverse effectSettore MED/25 - Psichiatriadiscontinuation ratesPsychiatric Status Rating Scalesrespectively). In multivariate analysisbusiness.industryLong-Acting Antipsychoticlong-acting injectable antipsychoticsSurvival AnalysisConfidence intervalparticipant refusal to continue LAIs and LAIs no longer being required were the most frequently reported reasons for discontinuation. Paliperidone LAI and aripiprazole LAI were the least discontinued medications (33.9 and 35.4%030227 psychiatryDiscontinuationProspective StudieAntipsychotic Agentoccurring in almost 40% of the entire sampleDelayed-Action PreparationsNeurology (clinical)business030217 neurology & neurosurgerybeing prescribed olanzapine LAI and poor medication adherence at baseline were signifcantly associated with higher discontinuation riskFollow-Up Studies

researchProduct